Travere Therapeutics (TVTX) total liabilities
Travere Therapeutics (TVTX) had total liabilities of $490.36M at the end of fiscal 2025 (December 31, 2025). That is 8.4% lower than the $535.05M of fiscal 2024. Figures as of 19 Nov 2026, 03:24 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $490.36M
- Change on fiscal 2024
- −8.4%
- Growth, 5 years
- +4.4% a year
- Growth, 10 years
- +8.7% a year
- Highest on record
- $629.73Mfiscal 2022
- Lowest on record
- $5.80Mfiscal 2012
- Fiscal years on record
- 142012–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Travere Therapeutics total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 4.4% a year; over ten years the rate was 8.7% a year. Across the 14 fiscal years on record (2012–2025), the highest was $629.73M in fiscal 2022 and the lowest $5.80M in fiscal 2012.
Total liabilities by fiscal year
Travere Therapeutics total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $490.36M | 8.4% down | |
| 2024 | $535.05M | 9.0% down | |
| 2023 | $588.10M | 6.6% down | |
| 2022 | $629.73M | 32.7% up | |
| 2021 | $474.52M | 19.8% up | |
| 2020 | $396.23M | 3.3% up | |
| 2019 | $383.60M | 1.9% down | |
| 2018 | $390.91M | 72.0% up | |
| 2017 | $227.21M | 4.5% up | |
| 2016 | $217.52M | 2.5% up | |
| 2015 | $212.29M | 22.9% up | |
| 2014 | $172.72M | 330.0% up | |
| 2013 | $40.17M | 592.6% up | |
| 2012 | $5.80M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| MiniMed Group MMED | $1.02B | 2026 |
| Adaptive Biotechnologies ADPT | $287.74M | 2025 |
| Heartflow HTFL | $58.81M | 2025 |
| CRISPR Therapeutics CRSP | $343.43M | 2025 |
| Travere Therapeutics TVTX | $490.36M | 2025 |
| Option Care Health OPCH | $2.13B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Travere Therapeutics, figure by figure
- Travere Therapeutics market cap
- Travere Therapeutics revenue
- Travere Therapeutics earnings
- Travere Therapeutics earnings per share (EPS)
- Travere Therapeutics P/E ratio
- Travere Therapeutics P/S ratio
- Travere Therapeutics P/B ratio
- Travere Therapeutics free cash flow
- Travere Therapeutics operating margin
- Travere Therapeutics dividend
- Travere Therapeutics shares outstanding
- Travere Therapeutics total debt
- Travere Therapeutics cash on hand
- Travere Therapeutics total assets
- Travere Therapeutics net assets (shareholders' equity)
- Travere Therapeutics return on equity (ROE)
- Travere Therapeutics return on invested capital (ROIC)
Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value
Travere Therapeutics total liabilities: questions and answers
How large are Travere Therapeutics's total liabilities?
Travere Therapeutics (TVTX) had total liabilities of $490.36M at the end of fiscal 2025 (December 31, 2025). That is 8.4% lower than the $535.05M of fiscal 2024.
What is the growth rate of Travere Therapeutics's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 4.4% a year; over ten years the rate was 8.7% a year.
What are the highest and lowest total liabilities figures on record for Travere Therapeutics?
Across the 14 fiscal years on record (2012–2025), the highest was $629.73M in fiscal 2022 and the lowest $5.80M in fiscal 2012.
How is Travere Therapeutics's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Travere Therapeutics it is on record here for 14 fiscal years, 2012 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Travere Therapeutics (TVTX) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/TVTX/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.